New hope for controlling Tough-to-Treat breast cancer
Disease control
Recruiting now
This study is testing if adding a new drug called JS105 to two standard breast cancer medications works better than the standard two-drug combination alone. It is for adults with a specific type of advanced breast cancer that has returned or spread and has a PIK3CA gene mutation.…
Phase: PHASE3 • Sponsor: Risen (Suzhou) Pharma Tech Co., Ltd. • Aim: Disease control
Last updated Mar 24, 2026 12:01 UTC